LEUVEN, Belgium, March 12 /PRNewswire-FirstCall/ --
- ThromboGenics Reports Pre-Tax Profit of EUR12.2 Million For 2008
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments that will make a real difference to patient care in a number of important therapeutic areas, is today issuing a business update and its financial results for the full year ending December 31, 2008.
During the last twelve months, ThromboGenics has made considerable progress across all aspects of its business culminating in the recent start of the Phase III clinical development program for its lead product microplasmin in back of the eye disease. The decision to start the Phase III program was based on the positive Phase II clinical results which were announced over the course of 2008.
In June 2008, ThromboGenics announced a further important corporate milestone, the signing of a high value strategic alliance with Roche for its novel anti-cancer antibody TB-403 (anti-PIGF). This deal, which generated an upfront payment of EUR30 million, has provided significant funding to allow ThromboGenics to invest in its other development programs.
The upfront payment from the Roche deal has enabled ThromboGenics to report a pre-tax profit of EUR 12.2 million in 2008.
Given its recent progress, ThromboGenics is confident that over the next eighteen months it will be able to generate significant shareholder value as it continues to maximize the value of its exciting product pipeline.
Microplasmin - Eye Disease: Positive results announced in Phase II
clinical trials for back of the eye indications. Positive results were
reported in ThromboGenics' Phase IIb (MIVI III) trial in patients with a
number of back of the eye conditions. The trial show
|SOURCE ThromboGenics NV|
Copyright©2009 PR Newswire.
All rights reserved